Short-term prognostic value of lipid measurements in patients with angina pectoris

Thrombosis and Haemostasis

Volumn 84, Issue 6, 2000, Pages 955-960

  Bolibar, I ^a   Von Eckardstein, A ^a   Assmann, G ^a   Thompson, S ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acute phase markers; Apolipoprotein A I; C reactive protein; HDL cholesterol; Hemostatic factors

Indexed keywords

ANTICOAGULANT AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIGITALIS; DIURETIC AGENT; FIBRINOGEN; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; NITRATE; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EUROPE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEMOSTASIS; HUMAN; INFLAMMATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0034537306     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614155     Document Type: Article

References (33)

1. Prevention of coronary heart disease in clinical practice: Recommendations of the second joint task force of European and Other Societies on coronary prevention
2. Coronary heart disease: Reducing the risk. The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view
3. Current concepts: High density lipoproteins - The clinical implications of recent studies
4. Quantification of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease
5. Lipoprotein Lp(a) excess and coronary heart disease
6. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
7. Dose, response relationships of serum lipid measurements with the extent of coronary stenosis: Strong, independent, and comprehensive
8. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography
9. Triglyceride-rich lipoproteins: Are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?
10. Interactions amongst insulin, lipoproteins, and hemostatic function relevant to coronary heart disease
11. Lipoproteins and acute phase response during acute infection. Interrelationships between C-reactive protein and serum amyloid-A protein and lipoproteins
12. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?
13. Hemostatic Factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
14. Production of C, reactive protein and risk of coronary events in stable and unstable angina
15. ECAT Angina Pectoris Study: Baseline associations of hemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography
16. A comparison of methods for the estimation of plasma low and very low density lipoprotein cholesterol: The lipid research clinics prevalence study
17. Myocardial infarction and mortality in the Coronary Artery Surgery Study (CASS) randomised trial
18. Quantitative methods in the review of epidemiologic literature
19. Normal triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Study
20. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
21. Relation between baseline and on treatment parameters and first acute major coronary events in the Air Force/Texas Coronary Atheroscelrosis Prevention Study (AFCAPS/TexCAPS)
22. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high, density lipoprotein cholesterol
23. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
24. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
25. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
26. Relation of components of insulin resistance syndrome to coronary risk
27. Insulin resistance and coronary heart disease
28. C-reactive protein adds to the predicitive value of total and HDL cholesterol cholesterol in determining risk of first myocardial infarction
29. Apolipoprotein A, I and B levels and the risk of ischaemic heart disease during a five year follow-up of men in the Quebec Cardiovascular Study
30. Cholesterol reduction yields clinical benefit. Impact of statin trials
31. The effect of pravastatin on coronary events after myocardial infaction in patients with average cholesterol levels
32. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
33. Effect of freezing and thawing on the immunoassay of Lipoprotein(a)